[Form 4] Immunome, Inc. Insider Trading Activity
Insider transaction summary for Immunome, Inc. (IMNM): Reporting person Jack Higgins, identified as an officer with the title Chief Scientific Officer, reported transactions dated 09/10/2025. He acquired 22,000 common shares by exercise/transaction code M at a price of $1.35 per share, bringing his reported direct beneficial ownership in common stock to 40,729 shares. The filing also reports derivative holdings: an employee stock option with a conversion/exercise price of $1.35 exercisable beginning 06/23/2032 and, following the reported transactions, 151,840 derivative securities are shown as beneficially owned. Vesting terms state 25% vested on 05/01/2023 with the remainder vesting in 36 equal monthly installments.
Riassunto delle operazioni insider per Immunome, Inc. (IMNM): la persona segnalante Jack Higgins, identificato come dirigente con il titolo di Chief Scientific Officer, ha riportato operazioni datate 09/10/2025. Ha acquisito 22.000 azioni ordinarie tramite esercizio/codice di transazione M a un prezzo di $1.35 per azione, portando la sua proprietà diretta beneficiaria in azioni ordinarie a 40.729 azioni. La dichiarazione riporta anche partecipazioni derivate: una opzione azionaria per dipendente con un prezzo di conversione/esercizio di $1.35, ejercitabile a partire dal 23/06/2032, e, a seguito delle operazioni riportate, 151.840 titoli derivati sono indicati come detenuti beneficiariamente. Le condizioni di vesting prevedono che il 25% sia maturato il 01/05/2023, con il resto che matura in 36 rate mensili uguali.
Resumen de operaciones insider para Immunome, Inc. (IMNM): la persona reportante Jack Higgins, identificado como un directivo con el título de Chief Scientific Officer, reportó operaciones datadas el 09/10/2025. Adquirió 22,000 acciones comunes mediante ejercicio/código de transacción M a un precio de $1.35 por acción, llevando su propiedad directa beneficiosa reportada en acciones comunes a 40,729 acciones. La declaración también reporta participaciones derivadas: una opción de acciones para empleados con un precio de conversión/ejercicio de $1.35, ejercitable a partir del 23/06/2032, y, tras las operaciones reportadas, 151,840 valores derivados se muestran como poseídos de forma beneficiosa. Las condiciones de vesting establecen que el 25% ya está adquirida el 01/05/2023 y el resto se adquiere en 36 cuotas mensuales iguales.
Immunome, Inc.의 내부 거래 요약(IMNM): 보고자 Jack Higgins는 Chief Scientific Officer 직함의 임원으로 확인되었으며 2025년 9월 10일에 보고된 거래를 보고하였다. 그는 M 거래 코드에 따라 주당 1.35달러의 가격으로 22,000주의 보통주를 취득하여 보고된 직접 유익 소유가 40,729주로 증가했다. 신고서에는 파생 보유도도 보고되었는데, 직원 주식매수 옵션의 전환/행사가격이 1.35달러이고 2023년 6월 23일 시작으로 행사 가능하며, 보고된 거래 이후 151,840개의 파생증권이 유익하게 보유된 것으로 표시된다. Vesting 조건에 따르면 2023년 5월 1일에 25%가 이미 취득되었고, 나머지는 36개월 동안 동일한 월간 할부로 취득된다.
Résumé des transactions d'initié pour Immunome, Inc. (IMNM) : la personne déclarant Jack Higgins, identifié comme un cadre avec le titre de Chief Scientific Officer, a déclaré des transactions datées du 10/09/2025. Il a acquis 22 000 actions ordinaires par exercice/code de transaction M à un prix de 1,35 $ par action, portant sa propriété bénéficiaire directe déclarée en actions ordinaires à 40 729 actions. Le dépôt indique également des positions dérivées : une option d'achat d'actions pour employé avec un prix de conversion/d’exercice de 1,35 $, exerçable à partir du 23/06/2032, et, suite aux transactions déclarées, 151 840 titres dérivés sont indiqués comme détenus bénéficièrement. Les conditions de vesting prévoient que 25 % soient acquis le 01/05/2023, le reste s'acquiérant en 36 versements mensuels égaux.
Zusammenfassung der Insider-Transaktionen für Immunome, Inc. (IMNM): Die meldende Person Jack Higgins, identifiziert als ein leitender Angestellter mit dem Titel Chief Scientific Officer, meldete Transaktionen mit dem Datum 10.09.2025. Er erwarb 22.000 Stammaktien durch Ausübung/Transaktionscode M zu einem Preis von $1,35 pro Aktie, wodurch seine gemeldete direkte begünstigte Eigentümerschaft an Stammaktien auf 40.729 Aktien anstieg. Die Einreichung berichtet auch Derivate-Holdings: eine Employee Stock Option mit einem Umwandlungs-/Ausübungspreis von $1,35, ab 23.06.2032 ausübbar, und nach den gemeldeten Transaktionen werden 151.840 Derivatewerte als begünstigt gehalten ausgewiesen. Vesting-Bedingungen sehen vor, dass 25% am 01.05.2023 erworben sind, der Rest in 36 gleichen monatlichen Raten erworben wird.
ملخص صفقات داخلية لشركة Immunome, Inc. (IMNM): الشخص المبلغ عنه جاك هيغينز، المعرف كإداري باللقب Chief Scientific Officer، أفاد بصفقات مؤرخة في 10/09/2025. اشترى 22,000 سهماً عصفورياً من خلال يَفْعَل/رمز الصفقة M بسعر $1.35 للسهم، مما رفع ملكيته المباشرة المفيدة المبلغ عنها من الأسهم العادية إلى 40,729 سهماً. كما تفيد الوثيقة بوجود ممتلكات مشتقة: خيار أسهم للموظفين بسعر تحويل/تمرين قدره $1.35 يبدأ قابليته/تنفيذه اعتباراً من 23/06/2032، وبعد الصفقات المبلغ عنها، يظهر 151,840 ورقة مشتقة كملك مفيد. تنص شروط الاستحقاق على أن 25% منها تم اكتسابها في 01/05/2023 مع اكتساب الباقي على مدى 36 دفعة شهرية متساوية.
Immunome, Inc. 的内部交易摘要（IMNM）： 报告人 Jack Higgins，被确认为具备 Chief Scientific Officer 职务的高管，披露日期为 2025-09-10。 他通过执行/交易代码 M，以每股 $1.35 的价格购买了 22,000 股普通股，使其在普通股中的直接有益所有权报为 40,729 股。 申报还显示派生证券持有：一项员工股票期权，转换/执行价为 $1.35，自 2032-06-23 起可行使，且在所披露的交易之后，显示有 151,840 份衍生证券被受益持有。 归属条款规定，25% 已在 2023-05-01 授予，剩余部分在 36 个月内以等额月供方式 vesting。
- Officer acquired 22,000 shares at $1.35 on 09/10/2025, increasing direct ownership to 40,729 shares
- Vesting schedule disclosed (25% vested 05/01/2023; remainder in 36 monthly installments), providing transparency on timing
- Derivative holdings reported with 151,840 securities beneficially owned following the transaction, clarifying total exposure
- None.
Insights
TL;DR: Routine insider option exercise and vesting increased executive's direct and derivative holdings; no new material change to control.
The Form 4 reports an officer-level option exercise/issuance of 22,000 common shares at $1.35 on 09/10/2025, increasing direct holdings to 40,729 shares and leaving 151,840 derivative securities reported post-transaction. The disclosed vesting schedule (25% on 05/01/2023 then 36 monthly installments) explains the timing of share acquisition. This appears operationally routine: typical employee equity vesting and option exercise rather than a corporate event likely to alter company control or capital structure materially. No cash-proceeds, debt changes, or extraordinary transfers are disclosed.
TL;DR: Disclosure aligns with Section 16 reporting; transaction appears consistent with standard executive compensation vesting.
The filer is identified as an officer (Chief Scientific Officer) and the filing was signed by an attorney-in-fact. The explanation clarifies the vesting schedule, indicating the transaction arises from scheduled vesting and/or option exercise. From a governance perspective, the filing fulfills Section 16 transparency requirements. The record shows no related-party transfers, sales, or exceptions that would raise immediate governance concerns based on the submitted content.
Riassunto delle operazioni insider per Immunome, Inc. (IMNM): la persona segnalante Jack Higgins, identificato come dirigente con il titolo di Chief Scientific Officer, ha riportato operazioni datate 09/10/2025. Ha acquisito 22.000 azioni ordinarie tramite esercizio/codice di transazione M a un prezzo di $1.35 per azione, portando la sua proprietà diretta beneficiaria in azioni ordinarie a 40.729 azioni. La dichiarazione riporta anche partecipazioni derivate: una opzione azionaria per dipendente con un prezzo di conversione/esercizio di $1.35, ejercitabile a partire dal 23/06/2032, e, a seguito delle operazioni riportate, 151.840 titoli derivati sono indicati come detenuti beneficiariamente. Le condizioni di vesting prevedono che il 25% sia maturato il 01/05/2023, con il resto che matura in 36 rate mensili uguali.
Resumen de operaciones insider para Immunome, Inc. (IMNM): la persona reportante Jack Higgins, identificado como un directivo con el título de Chief Scientific Officer, reportó operaciones datadas el 09/10/2025. Adquirió 22,000 acciones comunes mediante ejercicio/código de transacción M a un precio de $1.35 por acción, llevando su propiedad directa beneficiosa reportada en acciones comunes a 40,729 acciones. La declaración también reporta participaciones derivadas: una opción de acciones para empleados con un precio de conversión/ejercicio de $1.35, ejercitable a partir del 23/06/2032, y, tras las operaciones reportadas, 151,840 valores derivados se muestran como poseídos de forma beneficiosa. Las condiciones de vesting establecen que el 25% ya está adquirida el 01/05/2023 y el resto se adquiere en 36 cuotas mensuales iguales.
Immunome, Inc.의 내부 거래 요약(IMNM): 보고자 Jack Higgins는 Chief Scientific Officer 직함의 임원으로 확인되었으며 2025년 9월 10일에 보고된 거래를 보고하였다. 그는 M 거래 코드에 따라 주당 1.35달러의 가격으로 22,000주의 보통주를 취득하여 보고된 직접 유익 소유가 40,729주로 증가했다. 신고서에는 파생 보유도도 보고되었는데, 직원 주식매수 옵션의 전환/행사가격이 1.35달러이고 2023년 6월 23일 시작으로 행사 가능하며, 보고된 거래 이후 151,840개의 파생증권이 유익하게 보유된 것으로 표시된다. Vesting 조건에 따르면 2023년 5월 1일에 25%가 이미 취득되었고, 나머지는 36개월 동안 동일한 월간 할부로 취득된다.
Résumé des transactions d'initié pour Immunome, Inc. (IMNM) : la personne déclarant Jack Higgins, identifié comme un cadre avec le titre de Chief Scientific Officer, a déclaré des transactions datées du 10/09/2025. Il a acquis 22 000 actions ordinaires par exercice/code de transaction M à un prix de 1,35 $ par action, portant sa propriété bénéficiaire directe déclarée en actions ordinaires à 40 729 actions. Le dépôt indique également des positions dérivées : une option d'achat d'actions pour employé avec un prix de conversion/d’exercice de 1,35 $, exerçable à partir du 23/06/2032, et, suite aux transactions déclarées, 151 840 titres dérivés sont indiqués comme détenus bénéficièrement. Les conditions de vesting prévoient que 25 % soient acquis le 01/05/2023, le reste s'acquiérant en 36 versements mensuels égaux.
Zusammenfassung der Insider-Transaktionen für Immunome, Inc. (IMNM): Die meldende Person Jack Higgins, identifiziert als ein leitender Angestellter mit dem Titel Chief Scientific Officer, meldete Transaktionen mit dem Datum 10.09.2025. Er erwarb 22.000 Stammaktien durch Ausübung/Transaktionscode M zu einem Preis von $1,35 pro Aktie, wodurch seine gemeldete direkte begünstigte Eigentümerschaft an Stammaktien auf 40.729 Aktien anstieg. Die Einreichung berichtet auch Derivate-Holdings: eine Employee Stock Option mit einem Umwandlungs-/Ausübungspreis von $1,35, ab 23.06.2032 ausübbar, und nach den gemeldeten Transaktionen werden 151.840 Derivatewerte als begünstigt gehalten ausgewiesen. Vesting-Bedingungen sehen vor, dass 25% am 01.05.2023 erworben sind, der Rest in 36 gleichen monatlichen Raten erworben wird.
FAQ
What transaction did Jack Higgins report for IMNM on 09/10/2025?
How many IMNM shares does the reporting person beneficially own after the transaction?
What derivative holdings were reported by the insider in the IMNM Form 4?
What is the vesting schedule disclosed in the IMNM filing?
What is the reporting person’s role at Immunome (IMNM)?
